arrow
G

Gerardo Rosati

carlo hospital
H指数:32
被引数:3,773

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY

短期放疗用于局部晚期直肠癌且不适合化疗的老年患者:SOFT研究

2025-10-250
PRE
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial

液体活检综合基因组分析描绘了转移性结直肠癌的突变景观,以预测CAPRI-2 GOIM试验中FOLFIRI联合西妥昔单抗的抗肿瘤疗效。

2025-04-010
PRE
Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer
2024-03-220
PRE
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial
2023-06-012
PRE
Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
2023-06-011
OA
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

密码子特异性KRAS突变预测转移性结直肠癌中三氟尿苷/替匹拉西的生存益处

2023-03-0244
OAAI
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

Regorafenib单药治疗RAS突变型晚期结直肠癌 (STREAM) 患者的二线治疗: 一项学术,多中心,单臂,两阶段,II期研究

2023-02-012
OAAI
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial
2022-03-303
OA
Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial
2021-09-010
OAAI
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
2021-05-019
PREAI